SPRINT Trial: the Conversation Continues
The Systolic Blood Pressure Intervention Trial (SPRINT) endeavored to answer the following question: "Will lower blood pressure reduce the risk of heart and kidney diseases, stroke, or age-related declines in memory and thinking?" The main results were presented at Scientific Sessions 2015 and subsequently published online. At this time, it is important for the medical community, health care planners and policy makers to have interpretation and guidance from experts about the trial results currently available for help in synthesizing how those results may impact daily practice, clinical guidelines and future research. To accomplish this goal, Hypertension invited a panel of experts to provide insights. . . .
Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial)
Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study
Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines
Is the SPRINT Blood Pressure Treatment Target of 120/80 mm Hg Relevant for Children?
Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial
Snapshot Hemodynamics and Clinical Outcomes in Hypertension: Precision in the Measurements Is Key
Successes of SPRINT, but Still Some Hurdles to Cross
SPRINT: What Remains Unanswered and Where Do We Go from Here?
SPRINT Trial Results: Latest News in Hypertension Management